# A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

> **NCT03188666** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 44 (actual)

## Conditions studied

- Fibrodysplasia Ossificans Progressiva

## Interventions

- **DRUG:** REGN2477
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT03188666
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-26
- **Primary completion:** 2019-09-16
- **Final completion:** 2021-09-16
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2022-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03188666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03188666, "A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03188666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*